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Individual dose adjustment of cyclosporine (CsA) or tacrolimus (TAC), which are critical-
dose drugs widely used in transplantation, is important not only to prevent acute rejection but 
also to try and prolong graft (and patient) survival. New therapeutic regimens such as 
calcineurin inhibitor (CNI) sparing strategies have recently strengthened the need for fine 
individual dose adjustment of these drugs.  
A good treatment-personalization strategy should employ a marker or a set of markers with 1) 
strong relationships with therapeutic and/or adverse effects; 2) low intra-individual 
variability; 3) established, and ideally validated, target values; and 4) easy and fast 
measurement.  
So far, dose individualization has mainly been based on pharmacokinetics (PK), which 
monitors the handling of the drug by the body, but pharmacodynamics (PD), which focuses 
on the biologic effect of the drug on its target (1), might also be useful as a replacement or as 
an adjunct.  
Early on in the use of CsA, pre-dose (trough, C0) concentration monitoring became the 
standard of care (2). However, no trial has been conducted in transplantation to determine 
whether C0 monitoring is superior to no therapeutic monitoring with respect to efficacy or 
toxicity (2) and it would not be ethically acceptable now given the obvious improvements 
brought to transplant patients by TDM. However, it has long been recognized that C0 
monitoring is suboptimal, and retrospective analysis of transplant populations monitored on 
C0 has shown that the full inter-dose area under the concentration-time curve (AUC0-12h), 
abbreviated AUCs (AUC0-6h or AUC0-4h), or Cmax has a stronger link with the residual 
inefficacy or toxicity episodes than C0. Because of the impracticability of routine AUC0-12h 
monitoring, limited sampling strategies have been proposed as a more practical approach. In 
2002, the CONCERT International Consensus Statement even recommended monitoring all 
de novo and maintenance renal and liver transplant recipients with the CsA blood 
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concentration measured 2 hours post-dose (C2), based on the findings that C2 is the best single 
time-point predictor of AUC0-4h, which represents the period of greatest inter-individual 
variability of CsA pharmacokinetics, the best surrogate for Cmax, and which coincides with 
the period of maximal calcineurin and interleukin-2 (IL2) inhibition (2,3). A recent paper 
critically reviewed the randomized trials comparing C2 and C0 monitoring in terms of clinical 
benefits (4). In de novo renal, hepatic, and cardiac transplant recipients the most consistent 
finding was a higher mean CsA dose in the early postoperative period in C2 monitored 
patients, with no significant effect on the rate of acute rejection for a majority of these studies. 
In stable transplant recipients, the majority of studies showed that C2 monitoring resulted in a 
reduction in mean CsA dose, without obvious clinical benefit. Therefore, clinical evidence of 
the superiority of limited sampling strategies or C2 over C0 monitoring is still weak (2). 
C0 monitoring has been standard of care since tacrolimus approval, although its therapeutic 
ranges have since changed. A recent consensus conference emphasized the lack of 
concentration-controlled trials investigating the relationships between tacrolimus 
concentrations and clinical outcome, and from which tacrolimus target blood concentrations 
could be derived (5). However, a large randomized trial demonstrated that a regimen based on 
TAC with low therapeutic ranges may be advantageous for renal function, allograft survival, 
and acute rejection rates, as compared with regimens based on low-dose cyclosporine, low-
dose sirolimus, or standard-dose cyclosporine without induction (6). No randomized trial 
investigated the efficacy of alternative strategies to TAC C0 monitoring, such as other time 
points or AUC0-12 Bayesian estimation. Therefore, although C0 may not be a good surrogate to 
TAC inter-dose AUC in all situations, based on the available evidence it is still impossible to 
conclude whether one particular TDM strategy is more effective than the others (5).  
CNI concentrations in lymphocytes or in the transplanted organ might better predict efficacy 
than whole blood concentrations. Preliminary data suggest that in the early post-
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transplantation period, CsA intracellular concentrations or AUC0-12h in peripheral blood 
mononuclear cells (PBMC) would be lower in patients experiencing acute rejection or would 
decrease during the week preceding the acute rejection episode, and that TAC concentrations 
in PBMC would exhibit a very high inter-individual variability (7). However, at the present 
time, the extemporaneous isolation of PBMC from whole blood is laborious, LC-MS/MS is 
the only technique allowing the measurement of drug concentrations in such small sample 
volumes (even more so in patients with leucopenia), and these concentrations must be 
standardized per million cells or using a marker of cell number, all of which are rather 
imprecise. 
Studies in liver transplant recipients receiving TAC or CsA showed that intra-hepatic CNI 
concentrations were lower in patients with, than in those without, acute rejection, and that 
there was an excellent correlation of TAC intra-graft concentration with the severity of 
rejection, contrary to TAC whole blood concentrations (7). However, the determination of 
tissue CNI concentrations is unlikely to make its way into clinical practice (7). 
 
CsA and TAC bind to intra-cellular proteins called immunophilins, and the CNI-
immunophilin complex then inhibits calcineurin phosphatase activity. Calcineurin is involved 
in T-cell activation through dephosphorylation of the nuclear factor of activated T-cells 
(NFAT), enabling its translocation to the nucleus where it binds to the IL2 and interferon-γ 
(INF-γ) gene promoter regions, resulting in an increased secretion of the corresponding 
cytokines by the lymphocytes. Calcineurin also directly activates the lymphocytes by up-
regulating the expression of T-cell surface receptors, including the IL-2 receptor α chain 
CD25 and the transferin receptor CD71. 
Different approaches to pharmacodynamic monitoring of CNI therapy have been explored. 
The absence or weak inhibition of IL2 production in whole blood (8) or in CD8+ lymphocytes 
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(9) were described to be linked with a high acute rejection incidence in renal and liver 
transplant patients, respectively. Also, patients with a high pre-transplantation IL2 secretion 
were at higher risk of acute rejection after liver transplantation (9). However, to our 
knowledge no attempt has been made so far to try and individualize the CNI dose based on 
this biomarker. 
The inhibition of calcineurin phosphatase activity (CaN) can be measured reproducibly in 
PBMC isolated by Ficoll density gradient centrifugation. Most studies have shown that CaN 
correlates with blood CsA concentrations (in particular C2) in kidney transplant patients and 
with tacrolimus C2, but not C0, in liver and renal transplantation (10). However, not all studies 
have found a correlation between CaN and CNI blood concentrations, which might be due to 
the imprecision of CaN measurement, as well as imprecision of standardization by the number 
of cells or the protein content. However, the intra-individual variability in CaN in patients on 
CNI would be much larger than the assay variability, suggesting that PD monitoring should be 
performed on each occasion in each patient. Unfortunately, calcineurin activity measurement 
in PBMC currently takes almost 24 hours, which is not practical for routine use.  
Pre-dose CaN has been found to be an acceptable surrogate of the area under the CaN-time 
curve in renal and liver transplantation. Moreover, in both conditions as well as ex-vivo, CsA 
displayed deeper CaN inhibition than TAC (11), which is not consistent with the greater in-
vitro and clinical immunosuppressive effect of TAC, and suggests that this drug may have 
another mechanism of action. Anyway, owing to its inhibitory effect on hepatitis C virus 
replication not shared by TAC, CsA is also suspected to have a secondary mechanism of 
action. The relationships between CaN and clinical outcome are not clear. Conflicting results 
were found between CaN and graft-versus-host disease in stem cell graft recipients. In a rather 
small group of patients on TAC, nephrotoxicity was linked with lower CaN and acute 
rejection with higher CaN; however, CaN did not seem to be more predictive than C0 (12).  
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More generally, in patients on a CNI, the residual CaN in lymphocytes probably results from 
their pre-transplant CaN; the degree of activation of T lymphocytes; the intra-lymphocyte 
concentrations of CNI; and the intrinsic sensitivity of calcineurin to the CNI (13). Also, the 
relationships of enzyme inhibition with biologic function and, eventually, graft outcome 
remain to be clearly established.  
Another approach is to assess, by flow cytometry on T-lymphocytes stimulated in whole-
blood cultures, the expression and down-regulation of cell surface markers (e.g., CD25, 
CD71) as an estimate of cell activation, the percentages of cells expressing intracellular 
cytokines (IL2, TNFα, INFγ) as an indicator of T-cell function, and T-cell proliferation (1). In 
liver transplant recipients on CsA or TAC, pre-transplantation IL2 expression by CD8+ T 
cells (but not calcineurin activity) was higher in patients who subsequently developed acute 
rejection (9). The same was true for intra-cellular IL2 at the time of the rejection episode, and 
a positive correlation was found between the percentage of IL2 expressing T cells and 
calcineurin activity. TNFα and IL2 expression correlates with transplant patients’ age, and in 
healthy volunteers lymphocyte proliferation is higher in women (14), suggesting that a variety 
of factors can influence these biomarkers, many of which have probably not been investigated 
yet. 
Interestingly, T-lymphocyte activation and proliferation are not specifically linked with CNI 
effects as they are also affected by IMPDH or mTOR inhibition. Consequently, these tests 
might be used as markers of cellular immunosuppression rather than as markers of CNI 
effects, provided that their link with acute rejection and/or graft function is further 
demonstrated. However, such flow cytometry tests are still expensive, laborious, lengthy (up 
to 3-day incubation), and require that blood samples be analyzed within 24 hours of 
collection, which is far from being routinely applicable. 
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Finally, the detection and quantification by real-time PCR of mRNAs encoding inflammatory 
cytokines following ex-vivo cell activation might be used to monitor T-cell response. A weak 
expression of the NFAT-regulated IL2, INFγ, and GM-CSF genes was closely linked with the 
frequency of infections and cancer in kidney transplant recipients on CsA (15). In patients 
with CsA dose tapering, expression of the same genes measured at 2 hours post-dose 
significantly increased after CsA dose reduction (16). However, the superiority of gene 
expression measurement over classic therapeutic drug monitoring has not been demonstrated. 
Such methods still need to be tested for their clinical pertinence (1). 
To summarize the data, immunosuppression biomarkers have sometimes exhibited association 
with CNI exposure and/or clinical outcome, but the best parameters and methods to measure 
immune cell function in a fast and cost-effective way have still to be defined (1). All these 
tests suffer from long and cumbersome work-up and none have been validated prospectively 
by comparison to traditional TDM so far, nor used in clinical practice. The relationships 
between enzyme inhibition and biologic function, T-cell function and cellular rejection, acute 
graft rejection and graft function or survival (Figure 1) are probably not straightforward and 
need to be investigated in large patient populations before PD monitoring can be considered 
for individual dose adjustment.  
 
In conclusion, PK monitoring of cyclosporine and tacrolimus has been improved over the 
years by a try-and-error process. Although formal clinical evidence is weak, TAC monitored 
on C0 and/or CsA monitored on C2 have become the basis of immunosuppression in most 
countries, associated with very low rejection rates during the first year post-transplant. 
However, it could possibly (and in the present era of CNI minimization, may need to) be 
improved further by means of more sophisticated approaches, such as AUC Bayesian 
estimation, preferably after validation by randomized prospective trials. Treatment 
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personalization in transplantation may ultimately rely on the choice of the best drugs and the 
best starting doses using pre-transplant pharmacodynamic and/or pharmacogenetic tests, as 
well as on post-transplant pharmacokinetic and pharmacodynamic monitoring to compensate 
for post-transplantation changes, environmental factors and intra-individual variability (13). 
However, clinical evidence in favor of CNI PD monitoring is currently at the lowest level and 
clinical experience is close to nil. Before it can be envisaged as a treatment personalization 
tool in organ transplantation, many questions still have to be answered, starting with the best 
marker of immunity to use, the influence of the physiological changes and immune system 
stimulation occurring post-transplantation, the effects of each immunosuppressive drug and 
their combinations on these biomarkers, and leading up to the relationships between such 
markers and clinical outcome. Continued efforts should also be made for a better 
understanding of the impact of pharmacogenetics on immunosuppressant benefit/risk ratio.  
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Figure legend 
 
Figure 1: flow-chart of the pharmacokinetic fate and pharmacodynamic effects of calcineurin 
inhibitors.  
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